Derek Cowsert

News
First-Line Weekly Dose-Dense Chemotherapy Not Recommended for Epithelial Ovarian Cancer
07/05/2022
First-line weekly chemotherapy showed no improvement in PFS or OS compared to chemotherapy administered every 3 weeks among patients with epithelial ovarian cancer, according to a phase 3 trial.
First-line weekly chemotherapy showed no improvement in PFS or OS compared to chemotherapy administered every 3 weeks among patients with epithelial ovarian cancer, according to a phase 3 trial.
First-line weekly chemotherapy...
07/05/2022
Oncology
News
Incidence of Brain Metastases Requiring Radiotherapy in Patients With Metastatic Breast Cancer Associated with Breast Cancer Subtype
11/07/2022
A study of patients with metastatic breast cancer found incidence and time to development of brain metastases vary significantly by cancer subtype, with a high proportion of patients with ERBB2-positive and triple negative breast cancer most...
A study of patients with metastatic breast cancer found incidence and time to development of brain metastases vary significantly by cancer subtype, with a high proportion of patients with ERBB2-positive and triple negative breast cancer most...
A study of patients with...
11/07/2022
Oncology
News
FDA Approves Trastuzumab Deruxtecan for Patients With HER2-Low Breast Cancer
08/08/2022
On August 5, 2022, the FDA approved fam-trastuzumab deruxtecan-nxki, taken via intravenous infusion every 3 weeks for adult patients with unresectable or metastatic human epidermal growth factor receptor 2-low breast cancer.
On August 5, 2022, the FDA approved fam-trastuzumab deruxtecan-nxki, taken via intravenous infusion every 3 weeks for adult patients with unresectable or metastatic human epidermal growth factor receptor 2-low breast cancer.
On August 5, 2022, the FDA...
08/08/2022
Oncology
News
Etirinotecan Pegol Conveys No Benefit vs Chemotherapy for Patients With Metastatic Breast Cancer and Brain Metastases
08/12/2022
Phase 3 study findings showed treatment with etirinotecan pegol yielded no statistically significant difference in outcomes vs chemotherapy in patients with metastatic breast cancer and brain metastases
Phase 3 study findings showed treatment with etirinotecan pegol yielded no statistically significant difference in outcomes vs chemotherapy in patients with metastatic breast cancer and brain metastases
Phase 3 study findings showed...
08/12/2022
Oncology
News
Tumor Treating Fields Improve Overall Survival for Patients With Advanced Non-Small Cell Lung Cancer
01/09/2023
According to results from the phase 3 LUNAR trial, patients with platinum-resistant, stage 4 non-small cell lung cancer treated with standard therapy plus Tumor Treating Fields experienced meaningful improvement in overall survival compared...
According to results from the phase 3 LUNAR trial, patients with platinum-resistant, stage 4 non-small cell lung cancer treated with standard therapy plus Tumor Treating Fields experienced meaningful improvement in overall survival compared...
According to results from the...
01/09/2023
Oncology
News
Markers of Resistance to CDK4/6 Inhibition Among Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
03/09/2023
Patients with metastatic HR-positive, HER2-negative breast cancer with high CCNE1 and/or PLK1 expression exhibited poor response to CDK4/6 inhibitor palbociclib.
Patients with metastatic HR-positive, HER2-negative breast cancer with high CCNE1 and/or PLK1 expression exhibited poor response to CDK4/6 inhibitor palbociclib.
Patients with metastatic...
03/09/2023
Oncology
News
Pafolacianine Demonstrates Efficacy in Detection of Folate Receptor-Positive Ovarian Cancer
09/19/2022
Findings from a phase 3 study confirm the safety and efficacy of pafolacianine injection for real-time detection of folate receptor-positive ovarian cancer.
Findings from a phase 3 study confirm the safety and efficacy of pafolacianine injection for real-time detection of folate receptor-positive ovarian cancer.
Findings from a phase 3 study...
09/19/2022
Oncology
Conference Coverage
Endocrine Therapy Interruption to Pursue Pregnancy Does Not Affect Short-Term Recurrence Rates
12/09/2022
According to study results presented at the 2022 San Antonio Breast Cancer Symposium, patients with breast cancer who temporarily paused endocrine therapy to pursue pregnancy did not experience higher short-term recurrence rates.
According to study results presented at the 2022 San Antonio Breast Cancer Symposium, patients with breast cancer who temporarily paused endocrine therapy to pursue pregnancy did not experience higher short-term recurrence rates.
According to study results...
12/09/2022
Oncology
News
Tiragolumab Plus Atezolizumab Improves PFS vs Placebo Plus Atezolizumab in NSCLC: CITYSCAPE Trial
07/05/2022
Tiragolumab plus atezolizumab yielded improved objective response rates and PFS vs placebo plus atezolizumab as first-line treatment for patients with NSCLC in the phase 2 CITYSCAPE trial.
Tiragolumab plus atezolizumab yielded improved objective response rates and PFS vs placebo plus atezolizumab as first-line treatment for patients with NSCLC in the phase 2 CITYSCAPE trial.
Tiragolumab plus atezolizumab...
07/05/2022
Oncology
News
METex14 Splicing Alterations and MET Co-Amplification Associated With Synergistic MET Expression in NSCLC
10/21/2022
In a study of MET Exon 14 expression, whole transcriptome sequencing pinpointed splice sites associated with increased MET stability and oncogenesis in non-small cell lung cancer.
In a study of MET Exon 14 expression, whole transcriptome sequencing pinpointed splice sites associated with increased MET stability and oncogenesis in non-small cell lung cancer.
In a study of MET Exon 14...
10/21/2022
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use